vegf  (Elabscience Biotechnology)

Journal: Bioactive Materials

Article Title: Mesenchymal stromal cells-loaded 3D radially aligned composite scaffold with potentiated paracrine signaling for sequential bone regeneration

doi: 10.1016/j.bioactmat.2026.02.059

Figure Lengend Snippet: Temporal analysis of the BMSC paracrine profile on different scaffolds. (A) Confocal microscopy images from Live/Dead fluorescence staining of BMSCs encapsulated within the PCL/HAp-GelMA/BMSCs scaffold after 1, 3, 5, and 14 d of 3D culture (live cells, green; dead cells, red). (B) The concentrations of key paracrine factors (TGF-β, PGE2, VEGF, HGF, and BMP-2) from BMSCs cultured in different scaffolds, quantified from culture supernatants at day 3 and day 7. (C) Corresponding relative mRNA expression levels of TGFB1, PTGS2, VEGFA, HGF, and BMP-2 in BMSCs at day 3 and day 7, as determined by qPCR analysis. Data are presented as mean ± SD (n = 3) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns: not significant.

Article Snippet: ELISA kits for PGE2 (Cat. No. E-EL-0034), TGF-β (Cat. No. E-EL-0162), VEGF (Cat. No. E-EL-R2603), and HGF (Cat. No. E-EL-R0496) were purchased from Elabscience (Wuhan, China).

Techniques: Confocal Microscopy, Fluorescence, Staining, Cell Culture, Expressing

Journal: Frontiers in Cardiovascular Medicine

Article Title: Sex-specific lymphatic responses to estrogen shape atherosclerosis in high-risk mice

doi: 10.3389/fcvm.2026.1699372

Figure Lengend Snippet: VEGF-C 152s treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

Article Snippet: Mice received intraperitoneal (IP) injections of VEGF-C (152s) at a dose of 50 ng per 25 g of body weight [purified recombinant rat VEGF-C protein (152s), Fitzgerald, catalog no. 30R-AV006-22] or vehicle control (phosphate-buffered saline, PBS), administered three times per week for four consecutive weeks.

Techniques: Clinical Proteomics, Intravital Microscopy, Staining